Pharvaris (NASDAQ:PHVS) Shares Down 11.7% – Here’s What Happened

Pharvaris (NASDAQ:PHVS)’s stock price was down 11.7% during trading on Monday . The stock traded as low as $15.57 and last traded at $15.71. Approximately 7,724 shares were traded during trading, a decline of 82% from the average daily volume of 42,822 shares. The stock had previously closed at $17.80.

Pharvaris Stock Performance

The stock has a fifty day simple moving average of $19.83 and a two-hundred day simple moving average of $19.32. The stock has a market cap of $509.44 million, a PE ratio of -5.71 and a beta of -3.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC acquired a new position in Pharvaris in the 3rd quarter worth $106,000. Geode Capital Management LLC increased its position in shares of Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock worth $685,000 after acquiring an additional 5,753 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris in the third quarter worth about $57,000. Jane Street Group LLC purchased a new position in Pharvaris in the third quarter valued at about $526,000. Finally, Sphera Funds Management LTD. grew its stake in Pharvaris by 8.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock valued at $8,136,000 after purchasing an additional 36,027 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.